Correction Alternative mechanisms of miR-34a regulation in cancer

[1]  S. Shetty,et al.  p53 and miR-34a Feedback Promotes Lung Epithelial Injury and Pulmonary Fibrosis. , 2017, The American journal of pathology.

[2]  A. Brenner,et al.  Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors , 2017, Investigational New Drugs.

[3]  Junjiang Fu,et al.  The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis , 2017, Oncotarget.

[4]  A. Fabre,et al.  The role of epithelial–mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel‐resistant prostate cancer , 2017, Molecular oncology.

[5]  Yoshiaki Ito,et al.  Identification of targets of tumor suppressor microRNA-34a using a reporter library system , 2016, Proceedings of the National Academy of Sciences.

[6]  P. Dong,et al.  MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells , 2016, Journal of experimental & clinical cancer research : CR.

[7]  Luqing Zhao,et al.  DDX3X promotes the biogenesis of a subset of miRNAs and the potential roles they played in cancer development , 2016, Scientific Reports.

[8]  T. Colombo,et al.  Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex , 2016, Oncogene.

[9]  F. Slack,et al.  OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer. , 2016, Cancer research.

[10]  G. Piaggio,et al.  Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity , 2016, Journal of Experimental & Clinical Cancer Research.

[11]  S. Chuang,et al.  Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells , 2016, RNA.

[12]  Hsien-Da Huang,et al.  miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database , 2015, Nucleic Acids Res..

[13]  G. Calin,et al.  PDL1 Regulation by p53 via miR-34 , 2015, Journal of the National Cancer Institute.

[14]  Hui Ling,et al.  MicroRNA Processing and Human Cancer , 2015, Journal of clinical medicine.

[15]  J. Lieberman,et al.  miR-34 and p53: New Insights into a Complex Functional Relationship , 2015, PloS one.

[16]  A. Venkitaraman,et al.  Micro(mi) RNA-34a targets protein phosphatase (PP)1γ to regulate DNA damage tolerance , 2015, Cell cycle.

[17]  L. Yao,et al.  microRNA-34a inhibits epithelial mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through transforming growth factor-beta/Smad pathway , 2015, BMC Cancer.

[18]  E. Bowman,et al.  Increased MicroRNA-34b and -34c Predominantly Expressed in Stromal Tissues Is Associated with Poor Prognosis in Human Colon Cancer , 2015, PloS one.

[19]  X. Chen,et al.  Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. , 2015, Cellular signalling.

[20]  F. Slack,et al.  Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation , 2015, Cell cycle.

[21]  Zhi-xin Wang,et al.  miR-34a induces cellular senescence via modulation of telomerase activity in human hepatocellular carcinoma by targeting FoxM1/c-Myc pathway , 2015, Oncotarget.

[22]  Guifu Wu,et al.  Shear-sensitive microRNA-34a modulates flow-dependent regulation of endothelial inflammation , 2015, Journal of Cell Science.

[23]  P. Tassone,et al.  Mir-34: A New Weapon Against Cancer? , 2014, Molecular therapy. Nucleic acids.

[24]  Xing Chen,et al.  MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. , 2014, Cancer letters.

[25]  X J Li,et al.  MicroRNA-34a: a potential therapeutic target in human cancer , 2014, Cell Death and Disease.

[26]  Wei Yan,et al.  Two miRNA clusters, miR-34b/c and miR-449, are essential for normal brain development, motile ciliogenesis, and spermatogenesis , 2014, Proceedings of the National Academy of Sciences.

[27]  Lin He,et al.  miR-34/449 miRNAs are required for motile ciliogenesis by repressing cp110 , 2014, Nature.

[28]  H. Hermeking,et al.  The p53/miR-34 axis in development and disease. , 2014, Journal of molecular cell biology.

[29]  A. Cook,et al.  SIRT1 modulates miRNA processing defects in p53-mutated human keratinocytes. , 2014, Journal of dermatological science.

[30]  D. Lodygin,et al.  IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. , 2014, The Journal of clinical investigation.

[31]  H. Hermeking,et al.  miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment. , 2014, Cell reports.

[32]  T. Speed,et al.  A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression , 2014, Genes & development.

[33]  F. Camargo,et al.  Hippo Signaling Regulates Microprocessor and Links Cell-Density-Dependent miRNA Biogenesis to Cancer , 2014, Cell.

[34]  R. Knight,et al.  miR-34: from bench to bedside , 2014, Oncotarget.

[35]  S. Skapek,et al.  miR-34a is essential for p19Arf-driven cell cycle arrest , 2014, Cell cycle.

[36]  K. Metzner,et al.  Synthetic pre-microRNAs reveal dual-strand activity of miR-34a on TNF-α , 2014, RNA.

[37]  Y. Wang,et al.  OCT4 as a target of miR-34a stimulates p63 but inhibits p53 to promote human cell transformation , 2014, Cell Death and Disease.

[38]  H. Hermeking,et al.  SNAIL and miR‐34a feed‐forward regulation of ZNF281/ZBP99 promotes epithelial–mesenchymal transition , 2013, The EMBO journal.

[39]  Danli Xie,et al.  MicroRNA-34a Enhances T Cell Activation by Targeting Diacylglycerol Kinase ζ , 2013, PloS one.

[40]  Xiaozhao Lu,et al.  Thyroid hormone inhibits TGFβ1 induced renal tubular epithelial to mesenchymal transition by increasing miR34a expression. , 2013, Cellular signalling.

[41]  H. Hermeking,et al.  MicroRNA-34a regulates cardiac ageing and function , 2013, Nature.

[42]  Zachary D. Smith,et al.  DNA methylation: roles in mammalian development , 2013, Nature Reviews Genetics.

[43]  P. Gao,et al.  microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status. , 2013, Cancer biotherapy & radiopharmaceuticals.

[44]  H. Hermeking,et al.  Detection of miR-34a Promoter Methylation in Combination with Elevated Expression of c-Met and β-Catenin Predicts Distant Metastasis of Colon Cancer , 2012, Clinical Cancer Research.

[45]  F. Slack,et al.  miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. , 2012, Cancer research.

[46]  M. Negrini,et al.  Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence , 2012, Clinical Cancer Research.

[47]  D. Xie,et al.  TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. , 2012, Cancer cell.

[48]  G. Goodall,et al.  ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. , 2012, The Journal of clinical investigation.

[49]  Xiuping Liu,et al.  Epigenetic regulation of miR-34a expression in alcoholic liver injury. , 2012, The American journal of pathology.

[50]  C. Croce,et al.  Inflammation regulates microRNA expression in cooperation with p53 and nitric oxide , 2012, International journal of cancer.

[51]  S. Berberich,et al.  MicroRNA-34a Modulates MDM4 Expression via a Target Site in the Open Reading Frame , 2012, PloS one.

[52]  A. Bader.  miR-34 – a microRNA replacement therapy is headed to the clinic , 2012, Front. Gene..

[53]  Joana A. Vidigal,et al.  Intact p53-Dependent Responses in miR-34–Deficient Mice , 2012, PLoS genetics.

[54]  J. Byrd,et al.  Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia. , 2012, Cancer research.

[55]  S. Xiong,et al.  MiR-34a inhibits lipopolysaccharide-induced inflammatory response through targeting Notch1 in murine macrophages. , 2012, Experimental cell research.

[56]  R. deVere White,et al.  MiR‐34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53‐Rb pathway status , 2012, International journal of cancer.

[57]  Peter A. Jones.  Functions of DNA methylation: islands, start sites, gene bodies and beyond , 2012, Nature Reviews Genetics.

[58]  A. Amano,et al.  BRCA1 regulates microRNA biogenesis via the DROSHA microprocessor complex , 2012, The Journal of cell biology.

[59]  Hanmin Wang,et al.  Hypoxia-Induced Down-Regulation of microRNA-34a Promotes EMT by Targeting the Notch Signaling Pathway in Tubular Epithelial Cells , 2012, PloS one.

[60]  Xuedan Chen,et al.  Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells , 2012, BMC Molecular Biology.

[61]  A. Menssen,et al.  miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions , 2011, Cell cycle.

[62]  T. Mak,et al.  Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets , 2011, Proceedings of the National Academy of Sciences.

[63]  Päivi Heikkilä,et al.  MiR-34a Expression Has an Effect for Lower Risk of Metastasis and Associates with Expression Patterns Predicting Clinical Outcome in Breast Cancer , 2011, PloS one.

[64]  Robert Gentleman,et al.  An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription , 2011, Nucleic acids research.

[65]  Sharmila Shankar,et al.  Targeting Epigenetic Regulation of miR-34a for Treatment of Pancreatic Cancer by Inhibition of Pancreatic Cancer Stem Cells , 2011, PloS one.

[66]  H. Rehrauer,et al.  Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. , 2011, Blood.

[67]  M. F. Shannon,et al.  An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition , 2011, Molecular biology of the cell.

[68]  W. Walsh,et al.  microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review). , 2011, International journal of oncology.

[69]  Jonathan Hall,et al.  Suppression of Latent Transforming Growth Factor (TGF)-β1 Restores Growth Inhibitory TGF-β Signaling through microRNAs , 2011, The Journal of Biological Chemistry.

[70]  K. Kelnar,et al.  The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. , 2011, Nature medicine.

[71]  B. Verdoodt,et al.  Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas , 2011, Virchows Archiv.

[72]  Milind B. Suraokar,et al.  TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs , 2010, Nature.

[73]  G Melino,et al.  p63 and p73, the ancestors of p53. , 2010, Cold Spring Harbor perspectives in biology.

[74]  J. Settleman,et al.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.

[75]  A. Hata,et al.  Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. , 2010, Molecular cell.

[76]  Ryan M. O’Connell,et al.  MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. , 2010, Immunity.

[77]  D. Antonini,et al.  Transcriptional repression of miR-34 family contributes to p63-mediated cell cycle progression in epidermal cells. , 2010, The Journal of investigative dermatology.

[78]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[79]  H. Hermeking,et al.  Frequent Downregulation of miR-34 Family in Human Ovarian Cancers , 2010, Clinical Cancer Research.

[80]  Feng-ping Huang,et al.  MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251. , 2010, Archives of medical research.

[81]  Y. Pilpel,et al.  p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC , 2010, Cell Death and Differentiation.

[82]  G. Evan,et al.  p53 — a Jack of all trades but master of none , 2009, Nature Reviews Cancer.

[83]  Lijun Liu,et al.  Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples. , 2009, Biochemical and biophysical research communications.

[84]  Hiroshi I. Suzuki,et al.  Modulation of microRNA processing by p53 , 2009, Nature.

[85]  Abraham Weizman,et al.  Reduced levels of miR‐34a in neuroblastoma are not caused by mutations in the TP53 binding site , 2009, Genes, chromosomes & cancer.

[86]  Š. Pospíšilová,et al.  miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities , 2009, Leukemia.

[87]  A. Judge,et al.  Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. , 2008, Human gene therapy.

[88]  Dirk Winkler,et al.  miR-34a as part of the resistance network in chronic lymphocytic leukemia. , 2008, Blood.

[89]  M. Yamakuchi,et al.  miR-34a repression of SIRT1 regulates apoptosis , 2008, Proceedings of the National Academy of Sciences.

[90]  J. Espinosa,et al.  Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation , 2008, Cell cycle.

[91]  Carola Berking,et al.  Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer , 2008, Cell cycle.

[92]  A. Mills,et al.  The quest for the 1p36 tumor suppressor. , 2008, Cancer research.

[93]  L. Larsson,et al.  Combined IFN-γ and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells , 2007, Molecular Cancer Therapeutics.

[94]  Naoto Tsuchiya,et al.  Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells , 2007, Proceedings of the National Academy of Sciences.

[95]  Ying Feng,et al.  Supplemental Data P53-mediated Activation of Mirna34 Candidate Tumor-suppressor Genes , 2022 .

[96]  R. Stallings,et al.  MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells , 2007, Oncogene.

[97]  V. Tarasov,et al.  Differential Regulation of microRNAs by p53 Revealed by Massively Parallel Sequencing: miR-34a is a p53 Target That Induces Apoptosis and G1-arrest , 2007, Cell cycle.

[98]  L. Lim,et al.  A microRNA component of the p53 tumour suppressor network , 2007, Nature.

[99]  Yu Liang,et al.  BMC Genomics , 2007 .

[100]  Moshe Oren,et al.  Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. , 2007, Molecular cell.

[101]  Michael A. Beer,et al.  Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. , 2007, Molecular cell.

[102]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[103]  R. Shiekhattar,et al.  The Microprocessor complex mediates the genesis of microRNAs , 2004, Nature.

[104]  S. Berberich,et al.  MicroRNA-34 a Modulates MDM 4 Expression via a Target Site in the Open Reading Frame , 2015 .

[105]  Jiajun Du,et al.  The analysis of microRNA-34 family expression in human cancer studies comparing cancer tissues with corresponding pericarcinous tissues. , 2015, Gene.

[106]  F. Gao,et al.  Role of inflammation-associated microenvironment in tumorigenesis and metastasis. , 2014, Current cancer drug targets.

[107]  Jane Zhao,et al.  TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.). , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[108]  Magali Olivier,et al.  TP53 mutations in human cancers: origins, consequences, and clinical use. , 2010, Cold Spring Harbor perspectives in biology.

[109]  K. Polyak,et al.  Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.

[110]  A W Langerak,et al.  17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation , 2009, Leukemia.

[111]  Tsung-Cheng Chang,et al.  Widespread microRNA repression by Myc contributes to tumorigenesis , 2008, Nature Genetics.

[112]  P. Roy-Burman,et al.  Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. , 1995, The American journal of pathology.